Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
inflammation/rasvumus
Link salvestatakse lõikelauale
Leht 1 alates 538 tulemused
Methods of treating obesity using antioxidant inflammation modulators
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
I. Field of the Invention
The present invention relates generally to the fields of biology and medicine. More particularly, it concerns methods for the prevention and/or treatment of diseases, such as obesity, with antioxidant inflammation modulators (AIMs).
II.
Treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, alzheimer's disease and inflammatory bowel disease by using at least one bacterial strain from Prevotella
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF INVENTION
A product for use in the treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, alzheimers disease and inflammatory bowel disease comprising at least one isolated bacterial strain from the species Prevotellaceae, herein the strain is
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Diabetes and obesity affect numerous humans throughout the world, and are associated with or induces other diseases or conditions. In particular, diabetes and obesity are serious risk factors for diseases and conditions such as hypertension, gallbladder disease, cancer,
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Diabetes and obesity affect numerous humans throughout the world, and are associated with or induces other diseases or conditions. In particular, diabetes and obesity are serious risk factors for diseases and conditions such as hypertension, gallbladder disease, cancer,
Monoclonal antibody specific for PPAR gamma, hydridoma cell line producing the same, and method for detecting regulator related to diseases, including inflammation, cancer and metabolic diseases, using the same
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD
The present invention relates to a PPAR gamma-specific monoclonal antibody, a hybridoma cell line producing the same, and a method for detecting a regulator related to diseases including inflammation, cancer and metabolic diseases, using the same.
BACKGROUND ART
The protein PPAR
Lactic acid bacteria and its applications in immunomodulation and anti-inflammation
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The invention relates to a probiotic and a composition comprising the same. Particularly, the invention relates to a new lactic acid bacteria and its use in enhancing immunomodulatory and anti-inflammatory activity.
BACKGROUND OF THE INVENTION
Fermented food products contain
Use of Akkermansia muciniphila for treating inflammatory conditions
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Apr. 5, 2018, is named P224214US_WO_ST25_3429641.txt and is 858 bytes in size.
FIELD OF
N-acyl amino acid derivatives, a method for the preparation thereof, a pharmaceutical composition and use thereof as anti-allergic, anti-inflammatory and hypolipidemic agents
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to the field of bioorgmic chemistry and concerns N-acyl derivatives of amino acids and pharmaceutically acceptable salts thereof, novel processes for synthesis of said compounds as well as pharmaceutical compositions based on them and use thereof in medicine as
N-acylic aminoacid derivatives, method for the production thereof, pharmacological composition and the use in the form anti-allergic, anti-inflammatory and hypolipidemic agents
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to the field of bioorganic chemistry and concerns N-acyl derivatives of amino acids and pharmaceutically acceptable salts thereof, novel processes for synthesis of said compounds as well as pharmaceutical compositions based on them and use thereof in medicine as
Method for treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphene as active ingredient
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2009/007905, filed Dec. 29, 2009, which claims benefit of Korean Patent Application 10-2009-0022937, filed Mar. 18, 2009.
TECHNICAL FIELD
The
2-'4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine derivatives and related compounds as neuropeptide Y5 (NPY5) ligands for the treatment of obesity
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to 1,4-disubstituted piperidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans or animals.
Neuropeptide Y (NPY), first isolated
Anti-obesity potential of Calebin A
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF INVENTION
The invention in general relates to medicaments for obesity management. More specifically, it relates to anti-obesity potential of Calebin A.
DESCRIPTION OF PRIOR ART
Obesity is the most prevalent nutritional disorder in industrialized countries and is a growing problem in
Anti-obesity potential of Calebin A
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF INVENTION
The invention in general relates to medicaments for obesity management. More specifically, it relates to anti-obesity potential of Calebin A.
DESCRIPTION OF PRIOR ART
Obesity is the most prevalent nutritional disorder in industrialized countries and is a growing problem in
Methods of treating inflammatory conditions
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
REFERENCE TO SEQUENCE LISTING IDENTIFICATION
The Sequence Listing, which is a part of the present disclosure, includes a computer readable file "RUC.sub.--112WO_ST25.txt" generated by U.S. Patent & Trademark Office PatentIn version 3.5 software comprising nucleotide and/or amino acid sequences
Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The instant invention is concerned with acyl sulfamides and pharmaceutically acceptable salts and prodrugs thereof and their use as therapeutic. compounds, particularly in the treatment of obesity, of Type 2 diabetes mellitus (often referred to as non-insulin dependent
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
